What question did this study set out to answer?

This study aims to evaluate the impact of HLA-B*5701 screening on the risk of hypersensitivity to abacavir.

HLA-B*5701 Screening for Hypersensitivity to Abacavir

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial shows that HLA-B*5701 screening reduces hypersensitivity reactions in diverse populations, suggesting safer drug use.

This study aims to evaluate the impact of HLA-B*5701 screening on the risk of hypersensitivity to abacavir.
HLA-B*5701 screening conducted in a predominantly white population
Pharmacogenetic testing applied to assess risk of hypersensitivity
ClinicalTrials.gov number, NCT00340080 provided for study registry.
94% of patients tested do not carry the HLA-B*5701 allele and are at low risk for abacavir hypersensitivity
Pharmacogenetic testing effectively prevents the toxic effect of abacavir

Mallal et al. (2008) studied this question.

View Full Paper

Ask AI

Bookmark